Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week. Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; complete-response-letter deficiency list already has the discriminator after an inspector asking for batch records you cannot produce this week. 2. Keep Pause the pathway in force until complete-response-letter deficiency list is completed after an inspector asking for batch records you cannot produce this week for labeling negotiator. 3. Treat complete-response-letter deficiency list as Escalate safety review because both readings appear after an inspector asking for batch records you cannot produce this week. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision to drop a secondary turns on in complete-response-letter deficiency list.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether complete-response-letter deficiency list supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in complete-response-letter deficiency list, then the action for labeling negotiator - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Regulatory or exam hook Clinical and Evidence Strategy would cite - Clinical and Evidence Strategy finding in complete-response-letter deficiency list that a second reviewer can re-perform